Natco Pharma Ltd

Natco Pharma Dividend

Natco Pharma declared an interim dividend of ₹1.50 per equity share for FY 2026-27. The record date is set for August 20, 2026.

Natco Pharma Q1 FY27 Results: Net Profit ₹206.5 Cr, Down 57.0% YoY

Natco Pharma Ltd reported revenue from operations of ₹735.2 Cr (-44.7% YoY) and net profit of ₹206.5 Cr (-57.0% YoY) for Q1 FY27.

Key figure

Net profit ₹206.5 Cr · -57.0% YoY

Natco Pharma Board Meeting Date

Natco Pharma has scheduled a board meeting on August 14, 2026, to consider its quarterly financial results and a potential interim dividend.

Natco Pharma Regulatory Approval

Natco Pharma received tentative U.S. FDA approval for Olaparib tablets. The reference drug Lynparza reported USD 1.4 billion in U.S. sales.

Natco Pharma Merger & Restructuring Worth ₹1,060 Cr

Natco Pharma completed the acquisition of an additional 13.25% stake in Adcock Ingram for ₹1,060 Crore. This transaction increases Natco's total shareholding to 49%.

Value

₹1,060 Cr

Natco Pharma Legal & Regulatory

Natco Pharma received a ₹0.60 Crore GST demand including interest and penalties. The order relates to RCM reporting discrepancies for the 2020-2024 period.

Value

₹0.60 Cr

Natco Pharma Board Meeting Outcome

Natco Pharma's board approved a ₹1,069 Crore cash acquisition of Adcock Ingram Holdings. The deal lifts Natco's stake to 49% in the South African firm.

Value

₹1,069 Cr

Execution

Before end of July 2026

Natco Pharma Board Meeting Outcome

Natco Pharma announced a board-approved acquisition of its South African subsidiary for ₹1,400 Crore cash. The deal aims to expand its geographic footprint.

Value

₹1,400 Cr

Natco Pharma Board Meeting Outcome

Board approved a Rs 1,400 Cr investment in Natco Pharma Africa and a Rs 1,069 Cr purchase to raise its Adcock Ingram stake to 49%. The deals boost Natco’s footprint.

Value

₹2,469 Cr

Natco Pharma Management Change

Mr. Nadella Malleswara Rao, Vice President of Operations, has superannuated. He ceased his role effective June 30, 2026.

Natco Pharma Earnings Call: Key Takeaways

Natco Pharma reported Q4 FY26 revenue of ₹816.9cr and PAT of ₹269cr. The company is diversifying into Brazil, Canada, and South Africa to counter Revlimid decline.

Natco Pharma Regulatory Approval

Natco Pharma and Lupin received U.S. FDA approval for Eribulin Mesylate Injection. The product targets a USD 43.7 million market for metastatic breast cancer treatment.

Value

₹415.1 Cr

Natco Pharma Earnings Call: Key Takeaways

Natco Pharma faces a sharp transition as Revlimid-led super-profits decline, shifting focus to Brazil and Canada. Management guides for a significant 50% profit contraction in FY27 as it attempts to diversify earnings.

Natco Pharma Earnings Call: Key Takeaways

Natco Pharma reported FY26 revenue of INR 43,759 Mn and PAT of INR 14,185 Mn, driven by US generic launches and high export formulation contributions.

Natco Pharma Q4 FY26 Results: Net Profit ₹269 Cr, Down 33.7% YoY

Natco Pharma Ltd reported revenue from operations of ₹739.1 Cr (-39.5% YoY) and net profit of ₹269 Cr (-33.7% YoY) for Q4 FY26.

Key figure

Net profit ₹269 Cr · -33.7% YoY

Natco Pharma Financial Results

Natco Pharma approved audited FY26 financial results, reporting consolidated total revenue of ₹4,375.9 Crore. The Board also amended CSR and fair disclosure policies.

Natco Pharma Board Meeting Date

Natco Pharma scheduled a board meeting for May 29, 2026, to approve fiscal year financial results. The trading window remains closed for designated persons.

Natco Pharma Legal & Regulatory

Natco Pharma received a ₹4.92 Crore demand notice from NPPA for alleged overcharging on two drugs. The company reports no material impact on its operations.

Value

₹4.92 Cr

Natco Pharma Other Announcement

Natco Pharma Limited submitted its compliance certificate under Regulation 74(5) of SEBI (DP) Regulations for the quarter ended March 31, 2026. The registrar confirmed that securities received for dematerialization were processed and the depositories' records updated within 15 days.